206 related articles for article (PubMed ID: 21209028)
21. [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
Marek J
Vnitr Lek; 2010 Jul; 56(7):690-4. PubMed ID: 20842914
[TBL] [Abstract][Full Text] [Related]
22. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease.
Heald AH; Ghosh S; Bray S; Gibson C; Anderson SG; Buckler H; Fowler HL
Clin Endocrinol (Oxf); 2004 Oct; 61(4):458-65. PubMed ID: 15473878
[TBL] [Abstract][Full Text] [Related]
23. Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
Lambert K; Rees K; Seed PT; Dhanjal MK; Knight M; McCance DR; Williamson C
Obstet Gynecol; 2017 Jan; 129(1):185-194. PubMed ID: 27926659
[TBL] [Abstract][Full Text] [Related]
24. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
25. Normal long-term health-related quality of life can be achieved in patients with functional pituitary adenomas having surgery as primary treatment.
Ritvonen E; Karppinen A; Sintonen H; Vehkavaara S; Kivipelto L; Roine RP; Niemelä M; Schalin-Jäntti C
Clin Endocrinol (Oxf); 2015 Mar; 82(3):412-21. PubMed ID: 25039500
[TBL] [Abstract][Full Text] [Related]
26. Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process.
Flitsch J; Spitzner S; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2000; 108(7):480-5. PubMed ID: 11083069
[TBL] [Abstract][Full Text] [Related]
27. Quality of life in patients with a pituitary adenoma.
Johnson MD; Woodburn CJ; Vance ML
Pituitary; 2003 Sep; 6(2):81-7. PubMed ID: 14703017
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas.
Castinetti F; Nagai M; Morange I; Dufour H; Caron P; Chanson P; Cortet-Rudelli C; Kuhn JM; Conte-Devolx B; Regis J; Brue T
J Clin Endocrinol Metab; 2009 Sep; 94(9):3400-7. PubMed ID: 19509108
[TBL] [Abstract][Full Text] [Related]
29. Determinants of altered sleep-wake rhythmicity in patients treated for nonfunctioning pituitary macroadenomas.
Joustra SD; Kruijssen E; Verstegen MJ; Pereira AM; Biermasz NR
J Clin Endocrinol Metab; 2014 Dec; 99(12):4497-505. PubMed ID: 25210880
[TBL] [Abstract][Full Text] [Related]
30. The Epidemiology of Pituitary Adenomas.
Daly AF; Beckers A
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):347-355. PubMed ID: 32741475
[TBL] [Abstract][Full Text] [Related]
31. Pediatric pituitary adenoma: a series of 42 patients.
Pandey P; Ojha BK; Mahapatra AK
J Clin Neurosci; 2005 Feb; 12(2):124-7. PubMed ID: 15749410
[TBL] [Abstract][Full Text] [Related]
32. Aromatase P450 expression in human pituitary adenomas.
Gonzales PH; Mezzomo LC; Ferreira NP; Roehe AV; Kohek MB; Oliveira Mda C
Neuropathology; 2015 Feb; 35(1):16-23. PubMed ID: 25410472
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication.
Pereira-Lima JF; Marroni CP; Pizarro CB; Barbosa-Coutinho LM; Ferreira NP; Oliveira MC
Neuroendocrinology; 2004 Mar; 79(3):119-24. PubMed ID: 15103224
[TBL] [Abstract][Full Text] [Related]
34. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.
Mortini P; Barzaghi R; Losa M; Boari N; Giovanelli M
Neurosurgery; 2007 Jun; 60(6):993-1002; discussion 1003-4. PubMed ID: 17538372
[TBL] [Abstract][Full Text] [Related]
35. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.
Dekkers OM; Pereira AM; Romijn JA
J Clin Endocrinol Metab; 2008 Oct; 93(10):3717-26. PubMed ID: 18682516
[TBL] [Abstract][Full Text] [Related]
36. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
37. Paternal deprivation prior to adolescence and vulnerability to pituitary adenomas.
Sobrinho LG; Duarte JS; Paiva I; Gomes L; Vicente V; Aguiar P
Pituitary; 2012 Jun; 15(2):251-7. PubMed ID: 21701822
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of the disease-specific QOL-CD quality of life questionnaire for patients with Cushing's disease.
Cusimano MD; Huang TQ; Marchie A; Smyth HS; Kovacs K
Neurosurg Focus; 2020 Jun; 48(6):E4. PubMed ID: 32480368
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas.
Yener S; Ertilav S; Secil M; Akinci B; Demir T; Kebapcilar L; Yesil S
Med Princ Pract; 2012; 21(5):429-34. PubMed ID: 22398948
[TBL] [Abstract][Full Text] [Related]
40. Gender differences in presentation and outcome of patients with Cushing's disease in Han Chinese.
Huan C; Qu Y; Ren Z
Biomed Mater Eng; 2014; 24(6):3439-46. PubMed ID: 25227055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
